Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Drops By 16.2%

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) saw a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 8,090,000 shares, a decrease of 16.2% from the February 13th total of 9,650,000 shares. Currently, 6.5% of the company's stock are short sold. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 7.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Insider Buying and Selling at Lyell Immunopharma

In other Lyell Immunopharma news, Director Richard Klausner purchased 158,000 shares of Lyell Immunopharma stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average price of $0.60 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now owns 843,365 shares of the company's stock, valued at approximately $506,019. This trade represents a 23.05 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Charles W. Newton acquired 200,000 shares of Lyell Immunopharma stock in a transaction on Monday, March 17th. The shares were bought at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the completion of the purchase, the chief financial officer now directly owns 200,000 shares in the company, valued at $112,000. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 533,000 shares of company stock valued at $313,550 in the last ninety days. Insiders own 25.10% of the company's stock.

Remove Ads

Hedge Funds Weigh In On Lyell Immunopharma

Several hedge funds have recently made changes to their positions in LYEL. GSA Capital Partners LLP boosted its holdings in Lyell Immunopharma by 1,285.5% during the third quarter. GSA Capital Partners LLP now owns 354,815 shares of the company's stock worth $490,000 after buying an additional 329,205 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma during the 3rd quarter worth $52,000. Erste Asset Management GmbH acquired a new position in shares of Lyell Immunopharma in the 3rd quarter worth $82,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Lyell Immunopharma during the third quarter worth $52,000. Finally, Centiva Capital LP purchased a new stake in shares of Lyell Immunopharma during the third quarter valued at $31,000. Institutional investors and hedge funds own 66.05% of the company's stock.

Lyell Immunopharma Trading Up 8.5 %

LYEL stock traded up $0.05 during trading on Friday, hitting $0.58. The company had a trading volume of 1,287,155 shares, compared to its average volume of 1,048,095. The firm has a market capitalization of $170.79 million, a price-to-earnings ratio of -0.73 and a beta of -0.41. The business has a 50 day moving average of $0.61 and a 200 day moving average of $0.88. Lyell Immunopharma has a fifty-two week low of $0.48 and a fifty-two week high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, equities analysts predict that Lyell Immunopharma will post -0.78 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.